Top companies in Clinical-stage Biopharmaceuticals by Cyborg Score (2026)

The 8 highest-scored Clinical-stage Biopharmaceuticals companies in the AskCyborg corpus, ranked by Cyborg Score — a 1–10 rating from a bull-vs-bear AI analyst debate across 11 dimensions. Leading the table: AtaiBeckley Inc. (7/10), NervGen Pharma Corp (7/10), Trevi Therapeutics, Inc. (7/10).

#CompanyCyborg ScoreThe verdictOwnershipPeers
1AtaiBeckley Inc.7/10Diversified psychedelic pipeline with strong BPL-003 clinical data and potential 20% market share in TRD treatment offers compelling upside Public
2NervGen Pharma Corp7/10Clinical-stage biotech with potentially first pharmacological therapy for spinal cord injury and clear regulatory pathway.Public
3Trevi Therapeutics, Inc.7/10Clinical-stage biotech with potentially differentiated therapy for chronic cough in IPF; success depends on Phase 3 outcomes and regulatory Public
4Disc Medicine, Inc.6/10Clinical-stage hematology biotech with differentiated targets and strong balance sheet, but near-term catalysts clouded by FDA bitopertin dePublic
5Sagimet Biosciences Inc.6/10Early-stage biotech with promising FASN inhibitor portfolio targeting high-unmet-need metabolic diseases; Phase III progress could drive sigPublic
6OnKure Therapeutics, Inc.4/10Following transactions, OnKure is expected to have a cash runway through multiple clinical readouts and into Q4-2026.Public
7Pliant Therapeutics, Inc.4/10Turnaround opportunity dependent on oncology program success, but faces execution risk and cash runway constraints.Public
8Applied Therapeutics, Inc.3/10Distressed biotech acquisition reflecting clinical setbacks and cash burn that forced near-term strategic sale.Private

See also Clinical-stage Biopharmaceuticals industry research and the full industry ratings index.

Cyborg Scores (1–10) are synthesized by AskCyborg’s multi-agent analyst-debate framework across 11 dimensions, recalibrated weekly. How the score works · Methodology.